Article Text

Download PDFPDF
CASE REPORT
Successful osimertinib treatment in a patient who exhibited intramedullary spinal cord metastases of lung adenocarcinoma with an acquired EGFR T790M mutation
  1. Kohei Horiuchi1,
  2. Takanori Asakura1,2,
  3. Shinji Sakaguchi1 and
  4. Fumitake Saito1
  1. 1 Department of Pulmonary Medicine, Eiju General Hospital, Taito-ku, Tokyo, Japan
  2. 2 Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
  1. Correspondence to Dr Kohei Horiuchi, kohei.horiuchi17{at}gmail.com

Abstract

Intramedullary spinal cord metastases (ISCMs) of non-small cell lung cancer (NSCLC) constitute a serious if infrequent complication, characterised by rapid progression of neurological deficits, with poor prognosis. We describe a 52-year-old man with ISCMs secondary to lung adenocarcinoma who acquired the T790M mutation of the epidermal growth factor receptor (EGFR) after previous use of a first-generation EGFR tyrosine kinase inhibitor (TKI); he was successfully treated with osimertinib. This is the first report of the use of osimertinib in ISCMs: due to its high central nervous system activity, osimertinib could be useful for treating ISCMs secondary to NSCLC in patients who exhibit the T790M mutation.

  • neurooncology
  • spinal cord
  • lung cancer (oncology)
  • therapeutic indications
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors SS provided patient care. KH and TA wrote the initial draft of the manuscript. SS and FS supervised the study and suggested critical revisions regarding important intellectual content. All authors approved the final version as submitted to the journal.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.